drugset / Trial / NCT05601830
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Timeline
- Start
- 2022-10-09
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
Outcome
Outcome not reported
Stopped: “It did not reach the expected results of clinical trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QN-030a | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |